$LQDA

Bloch Stephen M sold $6.4M of LQDA (indirect holdings)

Bloch Stephen M sold 235,477 indirectly-held shares of Liquidia Corp (LQDA) at $27.13 ($6.39M total) on 2026-10-05.

Original reporting
SEC EDGAR · Bloch Stephen M
Published Oct 7, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Bearish
high confidence
Mentioned
$LQDA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDABearishLow
01

Why it matters

The director's full divestiture may be interpreted as a negative signal, potentially prompting short sellers and reducing buyer interest.

02

Market read

Primary insider sale of a director-sized stake; modest materiality but new information for traders.

03

What to watch

No prior insider purchases; the director may be diversifying holdings unrelated to company outlook.

Relevance 6/10Novelty 6/10Timing: post‑market filing

Background

SEC Form 4 filing discloses insider transactions. This is the first public report of the director's complete exit from Liquidia.

Company-level read

Ticker impact

$LQDABearishHigh confidence
Context

Director Stephen Bloch sold 235,477 shares at $27.13 each, total $6.4M, leaving zero holdings.

Expected impact

downward pressure as the market prices in the insider sell.

Evidence & confidence

A director exiting with a $6.4M stake is material and suggests reduced confidence, prompting short-term sell pressure.

Market effects

Biotech sector may see slight sell pressure from perceived insider weakness.

U.S. equity market, particularly Nasdaq biotech listings.

Limited to investors tracking Liquidia and related biotech peers.

Counterpoint

The sale could be driven by personal liquidity needs, not a lack of confidence in the company.

Key entities

  • Liquidia Corp

    Biotech firm listed on Nasdaq (LQDA).

  • Stephen M. Bloch

    Director of Liquidia who sold his entire stake.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Liquidia Jumps 6.3% After HC Wainwright & Co. Maintains Buy

Liquidia Corporation (LQDA) rose 6.3% to $36.27 after four firms raised price targets, with an average of $57. HC Wainwright & Co. maintained a Buy rating, lifting its target to $65. The upgrades reflect optimism about the company's prospects and pipeline potential, with a 29.0% average target increase. LQDA's market cap is $3.2B.

$LQDAMedAI 8/10

Morrisville’s Liquidia Settles All Litigation With United Therapeutics, Keeping YUTREPIA Available for PAH Patients

Liquidia Corporation settled all litigation with United Therapeutics, resolving six lawsuits. The agreement allows YUTREPIA, a treatment for pulmonary arterial hypertension, to remain available. Liquidia will pay $380.7 million across 2026 and 2027, funded by YUTREPIA sales and cash on hand. The company reported $222.7 million in YUTREPIA net sales for Q3 2026 and has $396.1 million in cash.

$LQDAMed

H.C. Wainwright raises Liquidia stock price target on settlement

H.C. Wainwright raised its price target for Liquidia Technologies (LQDA) to $65 from $58, maintaining a Buy rating. The stock has surged 21% over the past week following a settlement with United Therapeutics, resolving all pending lawsuits. The settlement removes litigation overhang and allows Liquidia to focus on its pipeline. Analysts have mixed outlooks on the company's future performance.